BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2021;137:1304-9. [PMID: 33512400 DOI: 10.1182/blood.2019003812] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Ioannou P, Karakonstantis S, Schouten J, Kostyanev T, Charani E, Vlahovic-Palcevski V, Kofteridis DP; supported by the ESCMID Study Group for Antimicrobial Stewardship (ESGAP). Indications for medical antibiotic prophylaxis and potential targets for antimicrobial stewardship intervention: a narrative review. Clin Microbiol Infect 2021:S1198-743X(21)00569-3. [PMID: 34653572 DOI: 10.1016/j.cmi.2021.10.001] [Reference Citation Analysis]
2 Voigtlaender M, Langer F. Management of Vascular Thrombosis in Patients with Thrombocytopenia. Hamostaseologie 2021. [PMID: 34933376 DOI: 10.1055/a-1675-7824] [Reference Citation Analysis]
3 Fattizzo B, Pasquale R, Bellani V, Barcellini W, Kulasekararaj AG. Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature. Front Immunol 2021;12:791429. [PMID: 34899761 DOI: 10.3389/fimmu.2021.791429] [Reference Citation Analysis]
4 Brodsky RA, Lee JW, Nishimura JI, Szer J. Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria? Br J Haematol 2021. [PMID: 34923628 DOI: 10.1111/bjh.17860] [Reference Citation Analysis]
5 Makharia A, Lakhotia M, Roy B. Primary Evans syndrome in an adult man. BMJ Case Rep 2021;14:e243051. [PMID: 34887288 DOI: 10.1136/bcr-2021-243051] [Reference Citation Analysis]
6 Yoo JJ, Chonat S. Evaluating ravulizumab for the treatment of children and adolescents with paroxysmal nocturnal hemoglobinuria. Expert Rev Hematol 2022. [PMID: 35502699 DOI: 10.1080/17474086.2022.2073215] [Reference Citation Analysis]
7 Gris J, Chéa M, Guillotin F, Fortier M, Bourguignon C, Mercier É, Bouvier S. Thrombosis and paroxysmal nocturnal haemoglobinuria. Thrombosis Update 2021;5:100074. [DOI: 10.1016/j.tru.2021.100074] [Reference Citation Analysis]
8 Capecchi M, Ciavarella A, Artoni A, Abbattista M, Martinelli I. Thrombotic Complications in Patients with Immune-Mediated Hemolysis. J Clin Med 2021;10:1764. [PMID: 33919638 DOI: 10.3390/jcm10081764] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Frazer-Abel A, Kirschfink M, Prohászka Z. Expanding Horizons in Complement Analysis and Quality Control. Front Immunol 2021;12:697313. [PMID: 34434189 DOI: 10.3389/fimmu.2021.697313] [Reference Citation Analysis]
10 Fakhouri F, Schwotzer N, Golshayan D, Frémeaux-bacchi V. The rational use of complement inhibitors in kidney diseases. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.02.021] [Reference Citation Analysis]
11 Bravo-pérez C, Carrillo-tornel S, García-torralba E, Jerez A. Persistent Large Granular Lymphocyte Clonal Expansions: “The Root of Many Evils”—And of Some Goodness. Cancers 2022;14:1340. [DOI: 10.3390/cancers14051340] [Reference Citation Analysis]
12 Gerber GF, Yuan X, Yu J, Cher BAY, Braunstein EM, Chaturvedi S, Brodsky RA. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria. Blood 2021;137:3670-3. [PMID: 33945618 DOI: 10.1182/blood.2021011548] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
13 Gurnari C, Nautiyal I, Pagliuca S. Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Ther Clin Risk Manag 2021;17:1343-51. [PMID: 34934322 DOI: 10.2147/TCRM.S273360] [Reference Citation Analysis]
14 Gerber GF, DeZern AE, Chaturvedi S, Brodsky RA. A 15-year, single institution experience of anticoagulation management in paroxysmal nocturnal hemoglobinuria patients on terminal complement inhibition with history of thromboembolism. Am J Hematol 2021. [PMID: 34800310 DOI: 10.1002/ajh.26414] [Reference Citation Analysis]
15 DeZern AE, Churpek JE. Approach to the diagnosis of aplastic anemia. Blood Adv 2021;5:2660-71. [PMID: 34156438 DOI: 10.1182/bloodadvances.2021004345] [Reference Citation Analysis]
16 Rehan ST, Hashmi MR, Asghar MS, Tahir MJ, Yousaf Z. Pegcetacoplan ‐ a novel C3 inhibitor for paroxysmal nocturnal hemoglobinuria. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.512] [Reference Citation Analysis]
17 Tamura S, Hori Y, Hiroi T, Morimoto M, Yamashita Y, Mushino T, Sonoki T. Pegcetacoplan for refractory paroxysmal nocturnal haemoglobinuria associated with the C5 genetic variant. Br J Haematol 2021. [PMID: 34796912 DOI: 10.1111/bjh.17963] [Reference Citation Analysis]
18 Giannotta JA, Fattizzo B, Barcellini W. Paroxysmal Nocturnal Hemoglobinuria in the Context of a Myeloproliferative Neoplasm: A Case Report and Review of the Literature. Front Oncol 2021;11:756589. [PMID: 34858830 DOI: 10.3389/fonc.2021.756589] [Reference Citation Analysis]